Navigation Links
UCLA scientists isolate the first stages of tissue production in human embryonic stem cells
Date:7/21/2010

Scientists at the UCLA Broad Stem Cell Research Center have described a population of cells that mark the very first stage of differentiation of human embryonic stem cells as they enter a developmental pathway that leads to production of blood, heart muscle, blood vessels and bone.

Researchers hope that these cells could one day be used for clinical treatments of a wide range of medical conditions as the discovery may help scientists create better and safer tissues for use in regenerative medicine. It also will allow scientists to better understand the differences between pluripotent stem cells, which can become every cell in the body, and cells that have lost their pluripotency and are on their way to becoming specific types of tissue cells.

The study appears today in the early online edition of the peer-reviewed journal Proceedings of the National Academy of Sciences.

"Scientists are very interested in understanding how cells that are pluripotent are directed to become specific tissues," said Dr. Gay Crooks, a professor of pathology and laboratory medicine and senior author of the study. "We want to know what it is that switches on and off to make a pluripotent cell no longer be pluripotent. In this study, we found a cell population that can help us understand these processes, as it is such a close relative to embryonic stem cells, but has lost the ability to be pluripotent."

During early development, human embryonic stem cells can follow three distinct developmental pathways to form the primary germ cell layers: the mesoderm, the ectoderm and the endoderm. These three germ cell layers then become all the tissues in the human body. In this study, Crooks and her team studied human embryonic stem cells that followed the mesoderm pathway, which gives rise to blood cells, blood vessels, cardiac cells, muscle, cartilage, bone and fat.

Dr. Denis Evseenko, lead investigator on the studies and an assistant researcher in the pathology and laboratory medicine department at UCLA, placed human embryonic stem cells into culture and, after three or four days, found a small subset of the cells that had lost a key cell surface marker characteristic of the pluripotent state and had gained a new marker that is a hallmark of mesodermal cells. Because the markers are displayed on the cell surface, Crooks said, specific antibodies can be used to isolate the human embryonic mesodermal progenitors (hEMP cells) from the other cells in culture.

"The hEMP cells are the earliest stage of cells that are transitioning from human embryonic stem cells into the cells of the mesoderm," she said. "While these hEMP cells appear to be committed to forming mesoderm, they have not yet determined what type of mesodermal tissue they will become. Because of this we hope they may serve as a source to produce large numbers of blood, bone or muscle cells, once we learn how to drive them further along the correct pathway."

Crooks's research program focuses on making blood stem cells from human embryonic stem cells. Studies have shown that the blood stem cells created from human embryonic stem cells in the lab lack some of the functions possessed by the blood stem cells found in bone marrow or umbilical cord blood. As a result, the blood from embryonic stem cells does not develop into an optimal immune system. Crooks hopes that hEMP cells could be used to create blood stem cells as powerful and potent as those found in bone marrow and cord blood, cells that would be safe to use in human to treat such diseases as leukemia and sickle cell anemia.

The hEMP cells were tested extensively to ensure they had lost the ability to form teratomas, encapsulated tumors with tissue or organ components. The ability to create teratomas is a hallmark of embryonic stem cells.

"Researchers agree that it is not a good idea to use pluripotent stem cells in people because of the risk that they might form teratomas," Crooks said. "The hEMP cells we isolated did not have the ability to make teratomas, so they should be a safer choice when thinking about developing therapies for use in humans."

Crooks and Evseenko are now studying how to best direct the hEMP cells into all the mesoderm cell lineages, including blood cells, and manipulate the cells so they become functional cells as they proliferate and differentiate.


'/>"/>

Contact: Kim Irwin
kirwin@mednet.ucla.edu
310-206-2805
University of California - Los Angeles
Source:Eurekalert

Related medicine news :

1. Scientists Pinpoint Area of Brain That Fears Losing Money
2. Scientists Discover How HIV Is Transmitted Between Men
3. Prevention Is Key Research Goal for Premature Babies, Scientists Say
4. Scientists Discover Molecular Pathway for Organ Tissue Regeneration and Repair
5. Scientists find donut-shaped structure of enzyme involved in energy metabolism
6. Neuroscientists reveal new links that regulate brain electrical activity
7. Two UCSF Scientists to Receive Prestigious Dementia Research Honor
8. Johns Hopkins scientists develop personalized blood tests for cancer using whole genome sequencing
9. Scientists Spot Genetic Fingerprints of Individual Cancers
10. Scientists Unravel Mysteries of Intelligence
11. MSU scientists develop more effective method of predicting lead-poisoning risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... , ... April 24, 2017 , ... ... designed to recognize elevated anxiety levels in people with addiction who are served ... Smart Patch, a biosensing wearable device that monitors heart and breath rates to ...
(Date:4/24/2017)... ... April 24, 2017 , ... Labs often perform the ... for lab operators and management to assess these processes with a critical eye—particularly ... unnecessary actions. , Created with the help of both internal and external ...
(Date:4/24/2017)... ... ... “The Saint with Trin, and Omega Station”: a triple feature offering nonstop action ... author, Chris Jackson. Chris Jackson grew up in Abilene, Texas. He now ... teaching English. He is heavily involved in the youth group of his local church. ...
(Date:4/24/2017)... ... , ... A 2-in-1 bottleless water appliance provides both purified ... Texas, here are the ways in which this technology can benefit dental offices: ... fresh, oxygenated water, with both cold and hot options. , Convenience for Dentists ...
(Date:4/22/2017)... NY (PRWEB) , ... April 22, 2017 , ... ... which shows that U.S. consumers can save an average of 70% when buying ... savings (up to 97%) are available when purchasing from other countries. The report ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... 20, 2017 NeuroVive Pharmaceutical AB (Nasdaq ... positive preclinical results demonstrating anti-fibrotic effects with ... steatohepatitis (NASH), in an additional well-validated experimental ... has previously shown similar anti-fibrotic effects in ... scientists present novel data demonstrating anti-fibrotic effects ...
(Date:4/19/2017)... , April 19, 2017  IRIDEX Corporation (Nasdaq: ... release financial results for the first quarter 2017 after ... The Company,s management team will host a corresponding conference ... ET. Investors interested in listening to the ... for domestic callers or (703) 326-3030 for international callers, ...
(Date:4/19/2017)... SAN DIEGO , April 19, 2017 /PRNewswire/ ... ("Sorrento"), an antibody-centric, clinical-stage biopharmaceutical company developing new ... today announced the closing of its previously announced ... common stock at a public offering price of ... commissions and estimated offering expenses payable by Sorrento.  ...
Breaking Medicine Technology: